Skip to search formSkip to main contentSkip to account menu

Antibody-Directed Enzyme Prodrug Therapy

Known as: ADEPT 
A systemic therapy which ensures that a specific prodrug is not converted into the active moiety anywhere but at the sites where the enzyme-linked… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Antibody-directed enzyme prodrug therapy (ADEPT) has been studied in a human ovarian carcinoma xenograft grown subcutaneously in… 
Review
2006
Review
2006
Antibody-directed enzyme prodrug therapy was conceived as a means of restricting the action of cytotoxic drugs to tumor sites… 
Highly Cited
2005
Highly Cited
2005
PURPOSE Antibody-directed enzyme prodrug therapy (ADEPT) requires highly selective antibody-mediated delivery of enzyme to tumor… 
Review
2004
Review
2004
Antibody-directed enzyme prodrug therapy (ADEPT) aims to restrict the cytotoxic action to tumour sites. The obstacles to achieve… 
Review
2001
Review
2001
The selective activation of prodrug(s) in tumor tissues by exogenous enzyme(s) for cancer therapy can be accomplished by several… 
1995
1995
Antibody-directed enzyme prodrug therapy (ADEPT) is a new approach to the treatment of solid cancers. In ADEPT, an antibody (or… 
Review
1994
Review
1994
The concept of generating cytotoxic agents from non-toxic prodrugs at tumour sites by antibody vectored enzyme introduces a wide… 
Highly Cited
1991
Highly Cited
1991
Following an extensive series of studies in nude mice with human xenografts a pilot scale clinical trial of antibody directed… 
Highly Cited
1991
Highly Cited
1991
Monoclonal anti-CEA antibody, A5B7, and its fragments conjugated to CPG2 localize to a peak concentration in the LS174T…